Dang Trang, Chan Wandy, Khawaja Sunnya, Fryar James, Gannon Brenda, Kularatna Sanjeewa, Parsonage William, Ranasinghe Isuru
The University of Queensland, Brisbane, QLD.
The Prince Charles Hospital, Brisbane, QLD.
Med J Aust. 2024 Sep 16;221(6):317-323. doi: 10.5694/mja2.52424. Epub 2024 Aug 27.
To assess the direct hospital costs for unplanned re-admissions within 30 days of hospitalisations with heart failure in Australia; to estimate the proportion of these costs attributable to potentially preventable re-admissions.
Retrospective cohort study; analysis of linked admitted patient data collections data.
SETTING, PARTICIPANTS: People admitted to hospital (all public and most private hospitals in Australia) with primary diagnoses of heart failure, 1 January 2013 - 31 December 2017, who were discharged alive and re-admitted to hospital at least once (any cause) within 30 days of discharge.
Estimated re-admission costs based on National Hospital Cost Data Collection, by unplanned re-admission category based on the primary re-admission diagnosis: potentially hospital-acquired condition; recurrence of heart failure; other diagnoses related to heart failure; all other diagnoses. The first two groups were deemed the most preventable.
The 165 612 eligible hospitalisations of people with heart failure during 2013-2017 (mean age, 79 years [standard deviation, 12 years]; 85 964 men [51.9%]) incurred direct hospital costs of $1881.4 million (95% confidence interval [CI], $1872.5-1890.2 million), or $376.3 million per year (95% CI, $374.5-378.1 million per year) and $11 360 per patient (95% CI, $11 312-11 408 per patient). A total of 41 125 people (24.8%) experienced a total of 58 977 unplanned re-admissions within 30 days of discharge from index admissions; these re-admissions incurred direct hospital costs of $604.4 million (95% CI, $598.2-610.5 million), or 32% of total index admission costs; that is, $120.9 million per year (95% CI, $119.6-122.1 million per year), and $14 695 per patient (95% CI, $14 535-14 856 per patient). Re-admissions with potentially hospital-acquired conditions (21 641 re-admissions) accounted for 40.1% of unplanned re-admission costs, recurrence of heart failure (18 666 re-admissions) for 35.6% of re-admission costs.
Unplanned re-admissions after hospitalisations with heart failure are expensive, incurring costs equivalent to 32% of those for the initial hospitalisations; a large proportion of these costs are associated with potentially preventable re-admissions. Reducing the number of unplanned re-admissions could improve outcomes for people with heart failure and reduce hospital costs.
评估澳大利亚心力衰竭患者住院后30天内非计划再次入院的直接医院费用;估计这些费用中可归因于潜在可预防再次入院的比例。
回顾性队列研究;对关联的入院患者数据收集数据进行分析。
设置、参与者:2013年1月1日至2017年12月31日期间因心力衰竭主要诊断入院(澳大利亚所有公立医院和大多数私立医院)、存活出院且出院后30天内至少再次入院一次(任何原因)的患者。
根据国家医院成本数据收集估算的再次入院费用,按基于首次再次入院诊断的非计划再次入院类别划分:潜在医院获得性疾病;心力衰竭复发;与心力衰竭相关的其他诊断;所有其他诊断。前两组被认为是最可预防的。
2013 - 2017年期间,165612例符合条件的心力衰竭患者住院(平均年龄79岁[标准差12岁];85964名男性[51.9%])产生直接医院费用18.814亿美元(95%置信区间[CI],18.725 - 18.902亿美元),即每年3.763亿美元(95% CI,每年3.745 - 3.781亿美元),每位患者11360美元(95% CI,每位患者11312 - 11408美元)。共有41125人(24.8%)在首次入院出院后30天内经历了58977次非计划再次入院;这些再次入院产生直接医院费用6.044亿美元(95% CI,5.982 - 6.105亿美元),占首次入院总费用的32%;即每年1.209亿美元(95% CI,每年1.196 - 1.221亿美元),每位患者14695美元(95% CI,14535 - 14856美元)。潜在医院获得性疾病导致的再次入院(21641次再次入院)占非计划再次入院费用的40.1%,心力衰竭复发(18666次再次入院)占再次入院费用的35.6%。
心力衰竭患者住院后的非计划再次入院费用高昂,产生的费用相当于首次住院费用的32%;这些费用的很大一部分与潜在可预防的再次入院有关。减少非计划再次入院的次数可以改善心力衰竭患者的预后并降低医院成本。